HER2 Positive Esophagogastric Cancer
Conditions
Keywords
Esophagogastric Adenocarcinoma, 5-Fluorouracil, Oxaliplatin, Lapatinib, Radiation Therapy, Surgery
Brief summary
With improvements in response rate and survival seen for HER2 positive patients treated with HER2 blockade in the metastatic setting, the use of HER2 blockade in the neoadjuvant setting to increase antitumor effect shows promise. Patients with previously untreated localized HER2 positive esophageal, GE junction and gastric adenocarcinomas will be enrolled. Patients meeting all inclusion/exclusion criteria will receive neoadjuvant treatment with concurrent chemotherapy and radiation therapy beginning on day 1 of treatment. During the lead-in safety portion, the optimal dose of lapatinib will be determined.
Detailed description
This is an open-label, non-randomized, Phase II study with a lead-in safety cohort. The study will evaluate the combination of 5-Fluorouracil, Oxaliplatin and Lapatinib with radiation therapy as neoadjuvant treatment for patients with previously untreated localized HER2 positive esophagogastric adenocarcinomas. Approximately 12 patients will be enrolled in the lead-in cohort to evaluate the safety of the combination. Following the lead-in cohort, Phase II will commence and up to 30 additional patients may be treated. The starting doses will be administered as follows: 5-FU 225 mg/mg2 continuous intravenous (IV) infusion Days 1 - 42 during XRT; Oxaliplatin 85 mg/m2 Days 1, 15 and 29, given by IV infusion, per institutional standard; Lapatinib Continuous PO daily dosing during XRT (final dose determined during lead-in cohort).
Interventions
DRUG5-Fluorouracil
5-FU, 225 mg/m2 IVCI, during XRT.
DRUGOxaliplatin
Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
DRUGLapatinib
Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
RADIATIONRadiation Therapy
Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
Sponsors
GlaxoSmithKline
SCRI Development Innovations, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed Stage I, II, or III adenocarcinoma of the esophagus (lower ⅓), GE junction, or gastric cardia. * Clinical stage I, II, or III as assessed by required baseline staging. In addition, patients with celiac node involvement (stage IVa) are eligible. * Patients must be surgical candidates based on stage and location of disease as well as other medical conditions and risk factors. * Positive HER2 status (overexpression and/or amplification of HER2 in primary tumor) as defined by FISH (HER2 FISH positivity). * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1. * Patient must be able to swallow and absorb oral medication. * Patients must have an indwelling central venous access catheter. * Adequate hematologic, renal, and hepatic function: * Known brain or leptomeningeal metastases. * Male patients willing to use adequate contraceptive measures. * Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to start of treatment. * Life expectancy ≥ 12 weeks. * Age ≥18 years of age. * Willingness and ability to comply with trial and follow-up procedures. * Ability to understand the nature of this trial and give written informed consent.
Exclusion criteria
* Patients with evidence of distant metastases are ineligible, as are patients who are not potential surgical candidates based on location or extent of local disease. Patients with celiac nodal disease (Stage IVa) will be allowed on study. * Previous anti-cancer treatment for esophageal, GE junction, or gastric cancer. * Any other investigational agents within the 28 days prior to day 1 of the study. * Known active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment). * Concurrent treatment with drugs known to be strong inhibitors or inducers of isoenzyme CYP3A that cannot be discontinued or switched to different medication prior to starting study drug. * Concurrent use of St. John's wort and grapefruit /grapefruit juice ≤7 days prior to starting study drug is not allowed. * Ongoing treatment with full-dose warfarin or its equivalent. Prophylactic treatment with 1 mg daily of warfarin and/or low molecular weight heparin is allowed. * History of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of a novel regimen, or that might affect interpretation of the results of this study or render the subject at high-risk for treatment complications. * Active gastrointestinal (GI) disease or other condition that in the opinion of the investigator will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (e.g. ulcerative disease, uncontrolled nausea, or vomiting). * Poorly controlled or clinically significant atherosclerotic vascular disease * A serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment. * Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis C (HCV). * Presence of other active cancers, or history of treatment for invasive cancer ≤5 years. Patients with stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible, as are patients with history of non-melanoma skin cancer. * Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol. * Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic Complete Response Rate (pCR Rate) | 18 months | Defined as the absence of invasive tumor in esophagogastric and lymph node tissue removed at time of surgery, as judged by the local pathologist. An improvement in pCR rate from 30 percent (historical) to 50 percent is the primary efficacy endpoint. |
| Safety and Optimal Dose of Regimen | 18 months | An additional primary objective is to evaluate the safety and optimal dose of lapatinib when added to 5-FU, oxaliplatin and radiation therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | 18 months | The Percentage of Patients Who Experience an Objective Benefit From Treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
| Toxicity Profile for Treated Patients | 18 months | Defined as the frequency of adverse events for patients who received at least one dose of study treatment, and assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. |
| Time to Progression (TTP) | 18 months | Time to progression is defined as the time between day 1 cycle 1 and time to first documented disease progression. Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
| Overall Survival (OS) | 18 months | The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Combined Therapy Combined Modality Treatment of Radiation therapy, 5-Fluorouracil, Oxaliplatin and Lapatinib followed by Surgery
5-Fluorouracil: 5-FU, 225 mg/m2 IVCI, during XRT.
Oxaliplatin: Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
Lapatinib: Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
Radiation Therapy: Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6 | 12 |
| Total | 12 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 1 |
| Overall Study | Death | 3 |
| Overall Study | Lost to Follow-up | 1 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Combined Therapy |
|---|---|
| Age, Continuous | 64 years |
| Region of Enrollment United States | 12 participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 12 / 12 |
| serious Total, serious adverse events | 6 / 12 |
Outcome results
Primary
Pathologic Complete Response Rate (pCR Rate)
Defined as the absence of invasive tumor in esophagogastric and lymph node tissue removed at time of surgery, as judged by the local pathologist. An improvement in pCR rate from 30 percent (historical) to 50 percent is the primary efficacy endpoint.
Time frame: 18 months
Population: All patients who underwent surgery
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Combined Therapy | Pathologic Complete Response Rate (pCR Rate) | 1 participants |
Primary
Safety and Optimal Dose of Regimen
An additional primary objective is to evaluate the safety and optimal dose of lapatinib when added to 5-FU, oxaliplatin and radiation therapy.
Time frame: 18 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Combined Therapy | Safety and Optimal Dose of Regimen | 750 mg QD Lapatinib |
Secondary
Overall Survival (OS)
The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death
Time frame: 18 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Combined Therapy | Overall Survival (OS) | NA months |
Secondary
Progression Free Survival (PFS)
The Percentage of Patients Who Experience an Objective Benefit From Treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: 18 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Combined Therapy | Progression Free Survival (PFS) | 3.253 months |
Secondary
Time to Progression (TTP)
Time to progression is defined as the time between day 1 cycle 1 and time to first documented disease progression. Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: 18 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Combined Therapy | Time to Progression (TTP) | 6.768 months |
Secondary
Toxicity Profile for Treated Patients
Defined as the frequency of adverse events for patients who received at least one dose of study treatment, and assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0.
Time frame: 18 months
Population: All treated patients
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Combined Therapy | Toxicity Profile for Treated Patients | Anorexia | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Dehydration | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Nausea | 9 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Diarrhea | 7 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Fatigue | 6 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Vomiting | 5 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Mucositis | 4 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Stomatitis | 3 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Anemia | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Constipation | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Dysesthesia | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Dysgeusia | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Dysphagia | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Esophagitis | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Cold sensitivity | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Hypokalemia | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Peripheral sensory neuropathy | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Thrombocytopenia | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Rash | 2 participants |
| Combined Therapy | Toxicity Profile for Treated Patients | Thromboembolic event | 2 participants |